68 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic
8-K
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic and other geopolitical events may disrupt Crinetics’ business
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
to and in support of the approval of a New Drug Application or applicable foreign regulatory approval; the COVID-19 pandemic may disrupt our business
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic and other geopolitical events may disrupt
8-K
EX-99.1
vr5aa862
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
EX-99.1
02szr
4 May 23
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
vckcat t4
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
sk3d3kw5n e5
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
EX-99.1
5vf71v8 gl
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
2gj cvjpvr5ziv98e33o
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
e9v kbbp8q
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
tsh1a
3 Oct 22
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
8:30am
8-K
EX-99.1
kwb3i5
12 Aug 22
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:41am